A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
作者信息
Wainberg Zev A, Melisi Davide, Macarulla Teresa, Pazo Cid Roberto, Chandana Sreenivasa R, De La Fouchardière Christelle, Dean Andrew, Kiss Igor, Jin Leei Woo, Goetze Thorsten O, Van Cutsem Eric, Paulson A Scott, Bekaii-Saab Tanios, Pant Shubham, Hubner Richard A, Xiao Zhimin, Chen Huanyu, Benzaghou Fawzi, O'Reilly Eileen M
机构信息
aDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
bUniversità degli studi di Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
出版信息
Future Oncol. 2025 Mar;21(7):765-774. doi: 10.1080/14796694.2025.2458458. Epub 2025 Feb 12.
Abstract
摘要
相似文献
1
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
Future Oncol. 2025 Mar;21(7):765-774. doi: 10.1080/14796694.2025.2458458. Epub 2025 Feb 12.
2
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
3
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma.
BMC Gastroenterol. 2025 Apr 17;25(1):266. doi: 10.1186/s12876-025-03867-2.
4
Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma.
Drugs. 2025 Feb;85(2):255-262. doi: 10.1007/s40265-024-02133-1. Epub 2025 Jan 17.
5
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2024 Jan 2;7(1):e2350756. doi: 10.1001/jamanetworkopen.2023.50756.
6
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.
Cost Eff Resour Alloc. 2024 Sep 18;22(1):70. doi: 10.1186/s12962-024-00578-5.
7
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Lancet Oncol. 2024 Dec;25(12):1655-1665. doi: 10.1016/S1470-2045(24)00511-4. Epub 2024 Nov 11.
8
Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China.
Front Pharmacol. 2024 Dec 20;15:1488645. doi: 10.3389/fphar.2024.1488645. eCollection 2024.
9
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4.
10
Gemcitabine/nab-paclitaxel in first line treatment of advanced pancreatic cancer - head-to-head comparison with the mFOLFIRINOX regimen.
Klin Onkol. 2024;37(5):331-334. doi: 10.48095/ccko2024331.
Zotero 插件